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ANNEXURES
INTRODUCTION
In India HIV/AIDS epidemic is now 22 years old. Within this short period it has 
emerged as one of the most serious public health problem in the country. Nearly six 
million people are estimated to be living with HIV/AIDS in south east Asia and CLHA 
less  than 15yrs  of  age are  estimated to  be 1,20,000 compared to  North America  of 
11,000.44 This  pandemic  has  caused the  death  of  over  17,000 in  200744 Over  6,800 
people are diagnosed positive for HIV a day, out of which 1200 are in children less than 
15yrs of age globally.44 The prevalence in children less than 15yrs of age is 3.8 % in 
India. Tamilnadu is considered as one of the high burden states in India, holding 10 % of 
the national PLHA.44
There are 2 types of HIV Virus, HIV –1 & HIV-2. The type common in the Indian 
Sub-continent is HIV -1 with major group M, sub group C whereas, sub group B is 
common  in  USA.  Perinatal  transmission  accounts  for  the  most  common  mode  of 
transmission in children. Other modes of transmission include breastfeeding and blood 
transfusion.25
The currently available antiretroviral (ARV) drugs and treatment of opportunistic 
infection have converted HIV infection into a chronic illness.34  The HIV disease may 
affect all body systems, including the cardiovascular system.34Since ARV drugs do not 
eliminate the HIV virus from the body, their use may simply postpone the development 
of heart disease, yet some of those drugs like zidovudine are cardiotoxic themselves and 
have been associated with heart disease.33,35
As  pulmonary  diseases  in  HIV  infection  are  more  effectively  prevented  and 
treated, the proportional morbidity and mortality of heart disease among children with 
HIV/AIDS  has  increased.5,37 Most  of  the  published  studies  about  heart  disease  in 
HIV/AIDS have been done in adults and abroad.6-9,36
The few published studies of heart disease among HIV infected children in India, 
have used a small sample size (<50) 7  or were highly selective (including only children 
with  symptomatic  HIV  disease  or  those  who  were  very  sick.)   In  many  clinical 
situations, HIV infected children are not routinely evaluated by echocardiography.
Previous studies have shown that heart diseases in HIV/AIDS patients are usually 
sub-clinical, but may be severe.8,4 When the signs and symptoms of cardiac dysfunction 
are present,  they are non-specific and are often attributed to non-cardiac pathologies 
especially pulmonary disease.23,39
From  the  beginning  of  the  HIV  epidemic  in  the  developed  world  it  was 
recognized that the heart could be involved, but that significant clinical involvement of 
the  heart  was  unusual.  On  further  review of  autopsy  series  and  clinical  series  and 
especially  with  the  study  of  patients  with  AIDS who had  echocardiography,  it  was 
apparent that abnormalities of the heart were seen frequently, even though symptomatic 
heart disease still remained unusual.11
According  to  the  western  literature,  cardiac  abnormalities  develop  at  a  high 
frequency  in  chronically  HIV  infected  individuals  irrespective  of  the  antiretroviral 
therapy,12,40 a fact which has been recognized, since the early years of the epidemic. The 
spectrum and epidemiology of cardiac disease in HIV infection have been extensively 
reviewed with the development of ventricular dysfunction and dilated cardiomyopathy 
being of particular clinical significance and occurring among HIV infected people at 
much higher rates than among HIV negative individuals45,  46,52.  Prevalence of cardiac 
diseases among the CLHA   in Sub Saharan Africa has been documented to be high.5,20 
The prevalence in the Indian sub continent has neither been estimated nor its impact on 
the survival.
Both infection with HIV and treatment of HIV infection with antiretroviral drugs47 
may affect the function of the heart and the vasculature. Direct infection of target tissues 
with  HIV,  inflammation  and  immunosuppression  secondary  to  HIV  infection  and 
common co-morbid  conditios  like malnutrition,  may  all  contribute  to  impairment  of 
cardiac function.47
Therefore the present study was undertaken to study the prevalence of cardiac 
disease and its clinical profile in HIV infected children. 
Etiopathogenesis
Pathogenesis of cardiomyopathy in HIV infection is poorly understood and it is 
likely to involve a combination of host, viral and environmental factors. 
Possible etiology: 
Infections HIV,  Toxoplasma  gondii,  Coxsackie  virus 
group  B,  Epstein  Barr  virus,  Adeno, 
cytomegalo virus
Cytokine mediated TNF- α, Nitric oxide, TGF -β, Endothelin-1
Auto immunity Anti cardiac myosin, Anti cardiac C protein
Drug related Zidovudine,Interferon,foscarnet, 
doxorubicin,IL-2, amphotericin B, cocaine
Nutritional deficiency Selenium, Vitamin B12, carnitine
 Autonomic 
dysregulation
Cardiovascular sympathovagal dysfunction 
Metabolic/Endocrine. Anemia,  Thyroid  hormone  related,  Growth 
hormone related,  Adrenal  insufficiency, 
Hyperinsulinemia.
Associations Encephalopathy,  immunodeficiency  (CD4 
<100), length of suppression, HIV viral load
Pathogenesis
Infection
Myocarditis is the best-studied cause of dilated cardiomyopathy in HIV disease.48 
HIV infects myocytes  but is not abundant (1 in > 2000 cells) or highly multiplicative in 
these cells.  Despite the paucity of evidence of direct myocyte involvement,  the HIV 
infection  clearly  causes  structural  and  functional  injury  to  the  heart  as  a  whole. 
Myocarditis  in  HIV  infection  is   mostly  of  unknown  etiology,  with  many  studies 
identifying an underlying pathology in only minority of cases, though cytomegalo virus, 
adeno  virus,Cox  sackie  virus  B3,  Epstein  Barr  virus,  Toxoplasma  gondii, 
Mycobacterium avium complex,  Candida  spp,  Crytococcus  neoformans,  Coccidiodis 
imitis, Histoplasma capsulatum, Aspergillus species and Pneumocystis jiroveci have all 
been documented.10,35
In  evaluating  whether  HIV itself  may  play  a  direct  role  in  induction of  local 
myocardial inflammatory response, contractile dysfunction, or pathologic remodeling, 
multiple investigators have detected HIV viral genome and/or viral proteins in the hearts 
of HIV infected people.10,51 
HIV virion infects myocardial cells in patchy distributions, without a clear direct 
association between HIV and cardiac myocyte dysfunction.48 How the virus enters CD 4 
receptor  negative  cells,  such  as  myocytes  is  unknown.  Non  myocyte  populations 
comprise of up to 70% of the total cellular constituency of the myocardium and consist 
of a mixed assemblage of cell types, including substantial populations of dendritic cells 
and  macrophages,  which  can  serve  directly  as  targets  of  HIV  infection.  This 
environment represents a volatile setting in the context of HIV infections.10 
Investigators using methods with a high degree of morphologic discrimination at 
the tissue level have in almost all cases found productive HIV infection to be restricted 
to cells within the myocardial interstitium, 50 most consistent with macrophages and T 
cells, such that previous long standing controversy over the potential for HIV to directly 
infect  cardiomyocyte  has  largely  been resolved.  The  virus  persists  in  reservoir  cells 
eg.dendritic  cells,  in  the  cerebral  cortex  and  in  macrophages  that  may  be  present 
between myocardial cells, even after effective ART.48 
Reservoir  cells  and  associated  cytokine  signaling  may  be  important  in  the 
development and progression of cardiomyopathy and encephalopathy. Reservoir cells, 
e.g. dendritic cells, may play a pathogenetic role in the interaction between HIV and the 
myocyte and in the activation of multifunctional cytokines eg. Tumor necrosis factor 
(TNF-α), Interleukins (1L-1, IL-6, IL-10) that contribute to progressive and late tissue 
damages.48
Another  potential  mechanism causing  tissue  damage  results  from lymphocytic 
myocarditis, an inflammatory process which has been documented at high frequencies in 
HIV infected people at later stage of disease progression and which constitutes one of 
several conditions known to predispose to development of DCM irrespective of HIV 
infection  status.50 The  inflammatory  infiltrates  in  HIV  associated  myocarditis  are 
consistently documented to mainly comprise of CD-8 receptor positive     T cells with 
variable number of macrophages and a paucity of CD-4 cells which may reflect  the 
decreased  CD-4:  CD-8  ratio  seen  in  HIV  positive  patients.   The  prevalence  of 
lymphocytic infiltration into the myocardium is as high as 52%.10,35
Cytokine mediated
Important  potential  contributor  to  development  of  HIV  cardiomyopathy  is 
proinflammatory  cytokine  excess  resulting  from effects  of  HIV  associated  cytokine 
dysregulation.  The most important cytokine is TNF – α. The local myocardial tissue 
environment  has  been  demonstrated  to  be  a  rich  potential  source  of  inflammatory 
cytokines, with both cardiomyocytes and locally resident non-myocytic interstitial cell 
populations competent to produce a variety of inflammatory mediators, and heart tissue 
capable of generating as much or more of TNF-α  per gram of tissue in response to 
endotoxin stimulation as liver or spleen.50 
Other cytokines implicated in the pathogenesis of HIV cardiac disease include 
IL-1, IL-2, IL-6, IF -δ,IL-1 and TNF can increase nitric oxide concentrations, which in 
turn can modulate inotropic response to catecholamines. IL-2 and IL-6   also have a 
negative  inotropic  effect  on  the  heart,  mediated  by  an  increase  in  nitrous  oxide 
production.50
The mechanisms by which the inflammatory cytokines generate their effects in 
the myocardium have been studied. Cytokine induced products of the sphingomyelinase 
pathways,  nitric  oxide  generated  by  inducible  nitric  oxide  systhetase  (iNOS),  and 
reduced  cyclic  AMP  response  to  β-adrenergic  stimulation  and  all  appear  to  act  as 
mediators of cardio depressant effects.
On a molecular level, these effect result from modulation of intra-cellular calcium 
transport, antagonism of cyclic AMP-mediated protein kinase A effects,  alteration of 
sensitivity  of  myofilaments  to  calcium binding,  S-nitrosylation  of  thiol  residues  on 
contractile proteins, functional uncoupling of - β adrenergic receptor stimulation from 
adenyl  cyclase  activity  and  possibly  alteration  of  β  -adreno  receptor  internalization 
kinetics. 50
Inflammatory cytokine-induced pathologic remodeling yields.
* Chamber dilatation
* Myocardial hypertrophy
* Fibrosis attributable to dysregulation of matrix metallo proteinases (MMP), tissue 
inhibitor of metallo proteinases (TIMP) balances, increased expression of TGF- β
* Alteration in susceptibility to cardiomyocyte apoptosis
  *      Stimulation of hypertrophy and foetal gene expression patterns
Auto immunity
Cardiac  specific  auto  antibodies  (anti  α  myosin  auto  antibodies)  have  been 
reported  in  up  to  30  %  of  patients  in  HIV  associated  cardiomyopathy.  Apparent 
improvement  of  left  ventricular  function  in  children  with  AIDS using  intravenously 
administered immunoglobulin is also suggestive of an immunologic etiology for the left 
ventricular dysfunction.13
Malnutrition
Nutritional causes for HIV related cardiac disease include selenium deficiency, L-
carnitine  deficiency  and  overall  malnutrition..10,52,53.  Levels  of  vitamin  B12,  growth 
hormone and thyroid hormone may also be altered in HIV disease and all have been 
associated with left ventricular dysfunctions.10,12
Wasting  syndrome  and  weight  loss  are  common  in  HIV  positive  patients, 
characterized by loss of lean body mass, especially muscle protein. In the absence of 
HIV  infection,  malnutrition  has  been  linked  to  decrease  in  LV  mass,  LV  volume, 
ventricular function and blood pressure.30 It is possible that inadequate nutrition may 
have contributed to the sub normal hypertrophic responses relative to LV dimension 
observed in these patients. Nevertheless, wasting is predictive of overall mortality and 
cardiac mortality in children with HIV. Severe anemia may also be a cause of as well as 
worsen the effect of cardiac disease in HIV positive patients.
Drug toxicity: 
The cardiovascular complications of commonly used pharmacotherapeutic agents 
in pediatric HIV infection 10
Zidovudine Cardiac  myocyte  toxicity(diffuse  destruction  of 
cardiac  mitochondrial   ultra  structures  and 
inhibition  of  mitochondrial   DNA  replication). 
hypersensitivity  reaction
Pentamidine Prolonged  QTc/  Torasade,  cardiac 
arrest/anaphylaxis, Hypotension, tachycardia
Trimethoprim 
sulphamethoxazole
Prolonged  QTc/  Torasade,  cardiac  arrest/ 
anaphylaxis, hyperkalemia.
Ganciclovir Ventricular tachycardia
Foscarnet Reversible  severe  cardiac  failure,  renal 
insufficiency, Electrolyte abnormalities.
Systemic 
corticosteroids
Ventricular hypertrophy/dysfunction.
Growth hormone Activation of rennin-angiotension system. 
Ventricular hypertrophy/dysfunction
Interlerleukin-2 Myocardial  depression,  myocarditis,infarction, 
arrythmias
Interferons: SVT,  cardiomyopathy,  coronaryartery  decreased 
perfusion / hypotension.
Mechanism by which HIV infection may adversely affect the vasculature
o Endothelial dysfunction.
o Lipid disorders associated with HIV infection.
o Viral protein related endothelial cell activation.
o Systemic inflammatory cytokine - chemokine dysregulation.
o Direct HIV infection of endothelium & vascular smooth muscle            cells.
o Enhanced atheroma formation by activated macrophages.
o   Prothrombotic state
Foetal and congenital effects of HIV infections
Evidence that either direct infection with HIV or developing in an HIV infected 
milieu could be related to foetal cardiac abnormalities, has been presented. *Vogel et al24 
studied 175 children who had perinatally acquired  HIV antibodies from their mothers. 
Five children had CHD including ASD,TOF,TA,VSD with PS.  The prevalence of 2.8% 
was significantly higher than the 0.8 % seen in the general population.25 Recent abstracts 
of   P2C2 longitudinal  study  found  a  high  prevalence  of  congenital  cardiovascular 
malformation in children born to mothers who were HIV positive.49 Foetal development 
in  a  mother  infected  with  the  HIV  with  the  concomitant  increase  in  cytokine  & 
nutritional deficiencies, other physiologic effects of maternal HIV infection, may also 
affect heart functions after birth, regardless of the HIV status of the child.
Cardiovascular manifestations of HIV disease
Recent studies have shown cardiac involvement in as, many as 45% to 65% 6-10of 
people infected with human immuno deficiency virus (HIV). 
Before the introduction of HAART the most common cardiac manifestations were 
dilated cardiomyopathy, endocarditis, myocarditis, pericarditis, right ventricular failure 
caused  by  pulmonary  hypertension  and  conduction  system  involvement.  However, 
recent reports of myocardial infarction in young HIV infected patients on HAART have 
raised concerns about premature coronary artery disease.47 
Dilated cardiomyopathy              
HIV disease is an important cause of dilated cardiomyopathy, with a prevalence 
reported of 3.6% among the CLHA. Patients with HIV infection and DCM can have a 
much worse prognosis than those with  DCM alone, hazard ratio of death 4.0.12
Pathological mechanism
There are several possible mechanisms for the increased LV dimension and mass 
in  pediatric  HIV  Infection,  including  HIV  effect,  after  load  excess,  and 
anemia/malnutrition,  none  of  which  fully  accounts  for  the  marked  dilatation  and 
hypertrophy that have been documented. HIV infection may directly or indirectly affect 
the cells of the pediatric heart. 
Pericardial effusion
Pericardial  effusion appears  to  be less  prevalent  in  children than in  adults.  In 
children with vertically transmitted HIV infection, pericardial effusion tends to occur 
less frequently and is small and progressive. Studies have documented a 16 % to 26% 
prevalence of pericardial effusion in HIV positive children.  22,31  69% of these children 
with effusion had associated cardiac abnormalities (ventricular dilatation or hypertrophy, 
myocarditis or pericarditis). Thus the relatively high prevalence of pericardial effusion 
reported in children may reflect upon children with more advanced disease.
Pericardial effusion in HIV disease may be related to opportunitic infection, but 
most  often  a  clear  etiology  is  not  found.  Miscellaneous  causes  are  capillary 
leak,wasting,malnutrition,hypothyroidism,prolonged acquired immunodeficiency.
The effusion may be a part of a generalized serous effusion process also involving 
pleural and peritoneal surfaces. The effect of HAART therapy in pericardial effusion is 
still largely unexplored.56     
Endocarditis
Few cases of endocarditis have been reported in children. 55 Right-sided valves are 
predominantly affected and the most frequent agents are staphylococcus aureus (>75%of 
cases),  streptococcus   pnemoniae,  haemophilus  influenzae,  candida  Albicans, 
Aspergillus  fumigatus  and  cryptococcus  neoformans.56  Non-bacterial  thrombotic 
endocarditis  also  known  as  marantic  endocarditis  ,  occcurs  in  3% to  5% of  AIDS 
patients mostly in the patients with HIV wasting syndromes.11 
Effect of HIV on the vasculature
HIV can damage endothelium through several mechanisms. Tat protein, a small 
cationic polypeptide that can be released from infected cells,  interact with at least 3 
different  types of receptors present  on the surface of endothelial  cells.  The resultant 
activation of several signal transduction pathways triggers the expression of adhesion 
molecules,  vascular  endothelial  growth  factors  and  platelet  activating  factors.  As  a 
consequence, Tat protein causes endothelial dysfunction. 56
Pulmonary hypertension: 
The  incidence  of  HIV-associated  pulmonary  hypertension  is  estimated  to  be 
1/200,  much  higher  than  the  1/200000  found  in  the  general  population.  Pulmonary 
hypertension has been documented in adults and children, often as a consequence of LV 
dysfunction,  repeated  respiratory  infections,  or  thrombo-embolic  disease,  but 
occasionally  as  a  primary  process  with  no  discernible  cause.  The  incidence  of 
pulmonary hypertension has been estimated to be 0.5% in hospitalized   patients with 
AIDS.10  
Therapy includes anticoagulation & pulmonary vasodilatation with Epoprostenol 
and Endothelin antagonist. Effects of HAART regimens on the clinical course of HIV 
associated pulmonary hypertension are unknown. The prognosis is poor with survival of 
6 months despite ART.     
Autonomic Dysfunction:
HIV infection has been associated with a wide spectrum of central and peripheral 
nervous system disorders, including autonomic dysfunction and neuropathy, which may 
occur  in  patients  at  any  stage  of  the  infection  and  have  significant  effect  on 
cardiovascular  reflexes.  The  hemodynamic  abnormalities,  dysrhythmias,  unexplained 
arrest and sudden death are common in the children infected with HIV especially when 
acute deterioration, intervention or neurologic involvement (encephalopathy) is present. 
The pathogenesis is unclear, could be directly associated with CNS effects, or vasculitis 
affecting peripheral nerves leading to depression of responses.
Clinical spectrum of cardiac abnormalities: 
• Chamber dilatation & hypertrophy       
• Ventricular dysfunction
• Congestive heart failure
• Pericardial effusion.
• Pulmonary hypertension.
• Congestive heart failure.
• Cardiac arrhythmias /arrest. 
Diagnosis of HIV associated cardiac disease
Physical examination: -
The symptoms of fever,  dyspnoea,  tachypnoea,  and tachycardia are commonly 
attributed  to  pulmonary  process  even  when  the  primary  pathology  is  cardiac.  The 
cardiac manifestations are mostly sub clinical and the findings on examination may not 
correlate with clinical severity.10,6
Chest Radiography: -
Cardiomegaly  or  pulmonary  congestion  may  be  evident  on  chest  radiographs. 
The chest x ray may often show no cardiomegaly despite ECHO proven disease.11
Electrocardiography:
ECG abnormalities  are  common.  The spectrum of  ECG abnormalities  seen  in 
children  who  are  HIV positive  are  tachycardia  (49%-70%),  ventricular  hypertrophy 
(20% - 30%). Other findings include ST segment and T wave changes (7%-33%) and 
rhythm disturbances including marked since arrhythmia, atrial ectopy, and ventricular 
arrhythmia.  24  hours  Holter  monitoring  is  useful  with  history  of  syncope  or 
hemodynamic abnormalities. 
Echocardiography:
Echo  has  been  the  best  non-  invasive  tool  to  accurately  estimate  the  cardiac 
dysfunction in the HIV infected patients. It is also useful for follow up. By Echo we 
estimate the LV fractional shortening and the ejection fraction. In the echocardiography 
LV  dysfunction,  hypertrophy  or  dilatations  are  the  common    abnormalities.  The 
prevalence  of  echo  abnormalities  varies  from  15  to  60  %.1-12 It  picked  up  dilated 
cardiomyopathy  (5%),  pericardial  effusion  (10  %),  pulmonary  hypertension,  RV 
dysfunction,  hypertrophy  and  cor  pulmonale.  Vascular  regurgitations  can  also  be 
found.Ejection fraction and fractional shortening are taken as indices of left ventricular 
systolic function
Endomyocardial biopsy:
Myocarditis is often patchy and so it needs multiple samples.It may significantly 
affect treatment. Viral PCR is potentially useful.10
Cardiac Troponin:  Troponin is a sensitive and specific marker of myocardial 
injury,  and the performance of  troponin assay is helpful  in a risk benefit  discussion 
about endomyocardial biopsy and in deciding the utility of intravenous immunoglobulin 
therapy in a particular patient.47
Brain Natriuretic peptide (N-terminal  pro B type Natriuretic Peptide):  It  has 
shown  to  be  very  sensitive  marker  for  symptomatic  and  asymptomatic  cardiac 
dysfunction,  prognosis,  severity  of  the  disease  and  response  to  therapy.  Studies 
performing screening of children with HIV for cardiac disease by BNP have started in 
the west.45  
Cardiac  Isoform  of  Alpha  2  macroglobulin:  Cardiac  isoform  of  Alpha  2 
macroglobulin, (CA2M)is a high molecular mass (182000mµ) , serum protein which is 
involved in the development of cardiac hypertrophy. Studies have confirmed that CA2M 
could be used as early a diagnostic marker for cardiac disease.38
Management
- The treatment for the heart failure and hypertension are similar to those in non-
HIV infected children.
- Treatment  of  certain  opportunistic  infections  with  appropriate  conventional 
antibiotic improves LV dysfunction. E.g.TB percarditis, cryptococcal, salmonella.
- Administration  of  HAART  has  shown  improvement  in  the  cardiac  function. 
Studies have shown that there is statistical difference between the groups with and 
without triple combination treatment as regards the presence of LV dysfunction.1
Some  children  with  heart  disease  and  congestive  heart  failure  who  are 
unresponsive  to  anticongestive  therapy  improve  with  intravenous  immunoglobulin 
therapy.13
Monthly  infusions  of  Intravenous  Immunoglobulin  to  HIV  infected  children 
appear to be associated with more normal LV structure and function compared with 
untreated infected children.  The Meta analysis showed a significant  increase in wall 
thickness and reduction in peak wall stress with IVIG and with elevated IgG levels.13
Prognosis
Factors  such  as  recurrent  bacterial  infections,  wasting,  encephalopathy,  male 
gender, low CD 4 and IgG levels, and an earlier age at AIDS diagnosis may identify 
high risk patients.
Cardiac manifestations of HIV infected children are protean and common. The 
ability  to  identify  patients  particularly  at  high  risk  for  cardiovascular  abnormalities 
would improve cure because care of HIV infected children relies on accurate diagnosis 
and prompt management of underlying illness, including symptomatic cardiac diseases.  
REVIEW OF LITERATURE
1. Ira Shah et al7 in 2003 at Mumbai prospectively evaluated 26 children in the 
age  group  1  to  9  years  with  perinatally  acquired  HIV  for  subclinical  cardiac 
abnormalities  during  a  period  of  six  months.  The  study  had  excluded  all  children 
presenting with signs and symptoms suggestive of cardiac pathology and evaluated the 
asymptomatic children by echocardiography. Of the 26 children, 20 children (76.9%) 
demonstrated abnormal echocardiographic findings.18 children (69.2%) in category B 
(symptomatic  HIV)  had  stastically  significant  abnormal  echocardiographic  findings 
(p<0.02).  The commonest  echocardiographic  abnormalities  seen were left  ventricular 
dilatation in 38.5% and left ventricular hypertrophy in 38.5% children.  In children with 
repeated lung infections pericardial  effusion was demonstated in 3 children (11.5%). 
Mild  tricuspid  regurgitation  was  present  in  3  cases.  The  relationship  of  cardiac 
abnormalities to the stage of HIV infections remained obscure.
He concluded that  echocardiographic  abnormalities  were  present  even in  HIV 
infected  children  who  were  asymptomatic  for  cardiac  symptoms.  The  study 
recommended  an  annual  echocardiographic  evaluation  to  assess  the  progression  of 
cardiac disease. 
2. Sulaiman Lubega et al3 in 2005 at Uganda recruited 230 HIV infected children 
in  a  cross  sectional  study  and   evaluated  clinically  and  investigated  them  by 
electrocardiography  and  echocardiography  following  the  criteria  of  the  American 
society of echocardiography. Heart abnormalities were detected in 51% of the children 
(40%  by  echocardiography  alone  and  26.5%  by  electrocardiography  alone).  Heart 
abnormalities were most prevalent in children with AIDS (76.2%) and least prevalent in 
children with asymptomatic HIV disease (25%). The abnormalities included were sinus 
tachycardia  (21%),  left  ventricular  systolic  dysfunction  (17%),  right  ventricular 
dilatation  (14%),  congenital  heart  disease  (48%),  dilated  cardiomyopathy  (3%), 
pericarditis (2.2%) and cor pulmonale (1.3%).
         3. Pong port Y et al6 studied the cardiac manifestations in HIV infected Thai 
children. He retrospectively reviewed the medical records of 27 infants infected with 
HIV perinatally, who presented with cardio vascular problems at a tertiary care hospital 
between 1995 and 2000. The mean age and initial cardiac evaluation was 36 months 
(range 8-65). Signs and symptoms included dyspnoea in all cases, edema in 12 (44%), 
finger  clubbing  in  11  (41%),  cyanosis  in  6  (22%)  and  S3  gallop  in  8  (30%). 
Echocardiographic  abnormalities  included  pericardial  effusion  in  12(44%),  right 
ventricular dilatation in 12 (44%), pulmonary hypertension in 11(41%), diminished left 
ventricular fractional shortening in 10 (37%), left ventricular dilatation in 9 (33%) and 
combined ventricular dilatation in 2 (7%) cases.  Left ventricular dysfunction did not 
correlate  with  HIV  CDC  classification,  age,  nutritional  status  or  clinical  signs  and 
symptoms.
   4. Lipshultz SE et al9 in (P2C2) 1998 studied 196 vertically HIV infected children 
with a baseline echocardiogram and 2 years follow up every 4 months. Although 88% 
had symptomatic HIV infection only 2 had congestive heart failure at enrollment, with a 
2 year cumulative incidence of 4.7%. All mean cardiac measurements were abnormal at 
baseline (decreased left ventricular fractional shortening and contractility and increased 
heart rate and LV dimension, mass and wall stresses). Most of the abnormal baseline 
cardiac  measurements  correlated  with  depressed  CD4  cell  count  Z  scores  and  the 
presence  of  HIV  encephalopathy.  The  study  concluded  that  sub-clinical  cardiac 
abnormalities  are  common,  persistent  and often  progressive.  Depressed  LV function 
correlated with immune dysfunction at baseline but not longitudinally, suggesting that 
CD4 cell count may not be a useful surrogate marker of HIV associated LV dysfunction 
and development of encephalopathy signals a decline in fractional shortening.
5.  The Prospective Pediatric and Cardiac Complications (P2C2) HIV multicentre 
study conducted by Starc et al8 in 1999 , where 205 HIV vertically infected children 
were enrolled at median age of 22 months. Most of the children had symptomatic HIV 
infection  (89%)  at  enrollment.  Children  underwent  cardiac  evaluation  including  2D 
echo, Doppler studies of cardiac function, 15 lead surface ECG, 24 hrs ambulatory ECG 
monitoring and a chest radiograph. The children who had cardiac impairment which was 
defined as having either LV fractional shortening <25% after 6 months of age, CHF or 
treatment with cardiac medications was 5.7%. The prevalence of echocardiographic LV 
enlargement (LV end diastolic dimension Z score >2) at the time of first echo was 8.3%. 
There  were  14  prevalent  cases  of  cardiac  impairment.  The  study  concluded  that  in 
addition to sub clinical  abnormalities an important  number of HIV infected children 
develop clinical  heart  disease.  The study recommended clinicians to maintain a high 
degree of suspicion for heart disease in HIV infected children and that all HIV infected 
infants and children should have a thorough base line cardiac evaluation.  
6.Maria Surely Bezerra Diogenes et al2 conducted a cardiac longitudinal study of 
children perinatally exposed to HIV type 1 from July 1996 to July 2004.The  objective 
was to determine the frequency of cardiac abnormalities and its natural history history in 
perinatally infected children.  The study concluded that electrocardiographic changes 
were significantly more frequent than clinical and echo findings. This study also said 
that higher prevalence of abnormalities was found among children belonging to the most 
advanced clinical and immunological category.
  7. Maria do Carno et al1 between 1999 and 2002 in Brazil conducted a cross 
sectional study with a cohort after18±6 months of AIDS diagnosis. The study included a 
total of 93 children with a confirmed diagnosis of AIDS with vertical transmission, with 
no  malignancies  and  who  underwent  echo.  Cardiac  abnormalities  were  assessed  in 
patients who were not treated (G1) and patients who were treated (G2) with combination 
anti  retroviral  therapy.  Cardiac  involvement  was  present  in  40  children  (43%).  The 
presence of left ventricular dysfunction (G 1:  39.10%; G 2: 10.60%) and the isolated 
enlargement of the left  ventricle (G 1: 6.60%; G 2: 14.90%) were the most frequent 
findings. A significant association between the groups without and with combination 
antiretroviral therapy as regards the presence of left ventricular dysfunction PR= 3.42 ;
( 1.41-8.26); p =0.02     and malnutrition PR= 1.79 ;( 1 – 3.20); p = 0.04 was observed.
         8.  Plein et al58 in 1999 studied the prevalence of cardiac abnormalities in a 
Pediatric  population  with  HIV.  About  22  children  had  cardiac  evaluation  by  echo. 
Cardiac lesions were found in 18% consisting of pericardial effusion in 3 children, wall 
motion abnormalities in 3 children and acute aortic endocarditis in one child. All cardiac 
abnormalities were staged as per CDC classification
STUDY JUSTIFICATION
Children  infected  with  HIV  may  develop  a  wide  range  of  cardiovascular 
abnormalities,  some of  which  are  to  be associated  with  poor  survival.  The  baseline 
echocardiographic abnormalities are common, persistent and often progressive. In many 
clinical situations, HIV infected children are not routinely evaluated by Echo. When the 
signs and symptoms of cardiac dysfunction are present, they are non specific and are 
often attributed to non cardiac pathologies especially pulmonary diseases.
Most of the published studies about heart disease in HIV / AIDS have been done 
in  adults.  Evidence  from adult  studies  cannot  be  easily  be  extrapolated  to  children 
because the epidemiologic correlates of adult high risk group may not apply to children. 
Adult  studies  are  also  confounded  by  traditional  cardiac  risk  factors  such  as  high 
cholesterol, diabetes,  alcohol and hypertension. Furthermore, adults do not suffer the 
congenital and foetal heart effects seen with HIV infection.
The published study of heart disease among HIV infected   children has used a 
small sample size. While considering the paucity of similar data regarding HIV infected 
children in the Indian sub continent, the present study was undertaken to determine the 
incidence and nature of clinical and sub clinical cardiac abnormalities in HIV infected 
children 
AIM OF THE STUDY
To determine: 
• the prevalence of cardiac dysfunction among CLHA in the age group of 2-12 
years in an urban referral  centre the clinical  and immunological  profile of the 
CLHA and  their association with cardiac dysfunction
• the  spectrum  of  cardiac  abnormalities  using  electrocardiography  and 
echocardiography
• and the utility of the symptomatology and investigations  in predicting cardiac 
dysfunction.
SUBJECTS AND METHODS
Methodology
Study design: Descriptive study
Study place: ART centre, ICH & HC
IP wards, ICH & HC
Cardiology department, ICH & HC
Study period: Jan. 2007 to June 2008
Inclusion criteria: 
Children living with HIV/AIDS between the age group 2-12 years attending ICH 
& HC.
Exclusion criteria:
Children with previously known acquired heart disease.
Manoeuvre
The study population comprised  of  102 CLHA.One child  who had previously 
known rheumatic heart disease was excluded from the study. Informed verbal consent 
was obtained from the parents or guardian for participation in the study. All children 
were examined according to the protocol mentioned in the proforma (annexure 1). Their 
anthropometric measurements were taken. Their haemoglobin status was determined by 
calorimetric method at the pathology lab,ICH. The CD-4 cell counts were done by flow 
cytometry at HIV wing microbiology department, Madras Medical College.
All the CLHA were subjected to cardiac studies. Chest radiography was taken. 
Electrocardiographic  studies  were  done  with  12  lead  standard  ECG  in  NIKHON 
KOHDEN Cardiofax 8820K machine.
Echocardiography was done by the cardiologist using the Philips En Visor C HD 
Echo  machine  in  2-dimensional  M-mode  with  Doppler  and  colour  flow  studies 
following  the  criteria  of  the  American  Society  of  Echocardiography.  59,  60,  64-65 The 
transducer frequencies used were 3.5, 5, 7.5Hz depending on the need. The parasternal, 
apical,  sub-xiphoid,  and the supra sterna views were used  to  define the  intracardiac 
measurements and indices of cardiac function. The parasternal and apical views were 
obtained with the patient in the left lateral or supine position depending on what gives 
the best view. The  parasternal long views with M mode were used for measuring the 
cardiac  dimensions  in  diastole  and  systole.  The  ventricular  ejection  fraction  and 
fractional  shortening was automatically  computed by the Echo machine by Teichole 
method. TR and PR gradients were estimated with doppler for assessment of pulmonary 
artery pressures.
Diagnostic definitions
Children who tested positive twice  with rapid antigen test  for  HIV   at  ART 
CENTRE, ICH were taken as HIV infected children.
HIV infection was considered to be vertically transmitted if the mother was HIV 
positive or had died of AIDS and there was no history of sexual  abuse of the child 
before enrolment.
Children were classified under four clinical stages based on the WHO Revised 
clinical  staging  for  HIV/AIDS  children  in  whom  diagnosis  of  HIV  infection  was 
confirmed. 60 (Annexure  2).
CLHA  who  reported  cardiac  symptoms  such  as  cyanosis,  dyspnoea,  fatigue, 
palpitations,  chest  pain  ,syncope  or  oedema  or  on  examination  had  evidence  of 
tachycardia, tachypnoea, increased jugular venous pressure, clubbing, cyanosis, shift of 
the apical impulse from the normal position for age, murmur or gallop were categorised 
as cardio symptomatic.
 CLHA  whose  weight  was  below  the  third  percentile  for  their  age  and  sex 
according to WHO growth charts 61 were taken as undernourished. 
 CLHA with haemoglobin >11gms% were considered as not anaemic; between 
7-10gms% as moderately anaemic and <7gms% as severely anaemic.62 
The  immune  status  of  the  CLHA  was  classified  based  on  CD4  cell  counts 
following the  CDC  Revised paediatric HIV classification based on the CD4 cell count.
(Annexure 3)25
Cardio thoracic ratio more than 0.5 in chest Xray was taken as cardiomegaly.
 ECG and ECHO studies  were  interpreted  by  the  cardiologists  as  per  standard 
guidelines of the American  heart association.59, 60,64-65
The following measurements were directly  obtained and analysed:  diameter  of 
right ventricle in diastole and systole, diastolic  and systolic dimensions of left ventricle, 
thickness  of  the  posterior  wall  of  left  ventricle  and  interventricular  septum  during 
diastole.
Ventricular dilatation and hypertrophy
 In assessing the reference echocardiogram measurements, the indicator used was 
body surface area (BSA). The Z score was calculated with base on the mean of expected 
measurements in normal children (normogram)64-66 with the same BSA  divided by a 
standard deviation. Therefore Z-score of zero represents the adjusted normal mean value 
and the upper and lower limits considered were +2 and -2.The ventricular dimensions 
above the upper limit were taken as LV and RV dilatation.
Ventricular systolic dysfunction
1. LV  systolic  dysfunction  was  defined  as  ejection  fraction  <54% and 
fractional  shortening <28%59  The severity  of  dysfunction  was  quantified 
based on FS and EF.1, 4
Dysfunction Ejection fraction
%
Fractional shortening
%
Mild 35-53 25-27
Moderate 20-35 19-24
Severe <20 <19
  
Dilated  cardiomyopathy was  defined  as  left  ventricular  dysfunction 
characterised by a diffuse decrease in myocardial contractility, with ejection fraction and 
fractional  shortening  below normal  limits  (FS<28% and  EF<20%)  followed  by  left 
ventricular enlargement with the diastolic diameter above normal values for BSA.59
Pericardial effusion was diagnosed when presence of   fluid was made out even 
in diastolic phase in the pericardial space. A small accumulation of pericardial fluid was 
defined as non–circumferential collection of effusion less than 10mm; moderate 10-20 
mm and severe greater than 20 mm.58
Regurgitation through the mitral and tricuspid valves were detected by Doppler 
and colour flow studies and were graded as mild, moderate and severe depending on the 
flow into the receiving chamber.
Diastolic  dysfunction  was  not  analysed  because,  unlike  the  systolic  function 
which can be directly arrived at, the diastolic function is complex and dependant upon 
number of factors such as age, preload, after load, heart rate and the coexistence of other 
abnormalities (e.g.  MV disease).  There is  no good single Echo measure to arrive at 
diastolic  function.  Doppler  measurements  of  ventricle  filling  pattern  should  not 
necessarily be viewed as the only reflection of ventricle diastolic function. It is a mistake 
to rely on single measurements such as E: A ratio or S: D ratio.59
Ejection fraction incorporates ventricular volume (3-dimensional parameter) and 
reflects global ventricular performance. Hence FS and EF were used to assess ventricle 
dysfunction.59
STATISTICAL ANALYSIS
For  continuous  variable  mean  is  reported.  To  examine  the  linear  trend  of 
proportions trend chi-square was used and to find the test of association chi-square was 
computed. To find the measure of association between the risk factor and the outcome 
variable odds ratio and its 95% confidence interval was computed. The diagnostic test 
procedure such as  sensitivity,  specificity,  PPV, NPV and accuracy of  the tests  were 
computed  to  assess  the  strength  of  the  test  procedure.   The  p  value  <  0.05  was 
considered to indicate statistical significance. All analysis were performed  using SPSS 
(Statistical Package for Social Sciences ) version 10.0.
RESULTS
Total no. of CLHA in the study = 102
Total no. of CLHA analysed in the study = 101
Total no. of CLHA excluded from the study = 1*
*(One child with the previously known acquired (rheumatic) heart disease was excluded 
from the study).
The results of the analysis are tabulated as follows:
Age and sex distribution of the CLHA
The average age of presentation was 6 years among the CLHA and 61.4% were 
male and 38.6% were female children. The difference in proportion between the male 
and  female  children  across  the  different  age  groups  was  not  statistically  significant 
(Table: 1).  
Table 1: Age and sex distribution of the CLHA.
Age group 
(yrs)
Male Female
n % n %
TOTAL
2-5 27 61.4 17 38.4 44
6-9 24 54.5 20 45.5 44
10-12 11 84.6 2 15.4 13
Total 62 61.4 39 38.6 101
(p = 0.147;    X2 = 0.36)
Mode of transmission in the CLHA
Table 2: Mode of transmission in the CLHA
Transmission N %
Mother to child 90 89.1
Breast feeding (surrogate mother) 1 1.0
Unknown 10 9.9
Perinatal transmission was the most common mode of transmission in the CLHA. 
Most of the children had acquired the infection by vertical transmission (89.1%). One 
case had acquired it by breast feeding from a surrogate mother. Among them 21 (20.7%) 
children had lost their mother due to the disease and in the rest (68.3%) the mothers 
were  positive for RVD. In the remaining 9.9% the route of transmission could not be 
ascertained (Table 2).
Clinical manifestations in the CLHA 
The  common  clinical  manifestations  in  the  CLHA  were  hepatosplenomegaly 
(46.6%),  followed  by  lymphadenopathy  (18.8%)  and  oral  candidiasis  (15.8%). 
Encephalopathy  was  present  in  9(8.9%)  cases  Tuberculosis  was  present  in  14 cases 
(13.8%), chronic diarrhoea was present in 11.8%, pneumonia excluding tuberculosis was 
present in 8.9% and upper respiratory tract infections including CSOM and rhinitis was 
present in 6%.(Fig.1).
Among  them  13  children  were  classified  under  WHO  clinical  
stage 1 (12.9%). The stage 2 and the stage 3 had an equal number of 24 cases each 
(23.8%). Rest of them presented in the advanced clinical stage (stage 4) of the disease 
(39.6%) (Fig: 2).  
Nutritional status of the CLHA:
The average weight of the CLHA was 14 kgs and the mean haemoglobin was 
9.3gms%  .The  study  population  comprised  of  71  (70%)  undernourished  children. 
Among them 10(9.9%) of them had severe anaemia (<7gms %) and 51(50.5%) of them 
had moderate anaemia       (7-10gms %)( Fig: 3).
Duration of illness and therapy of the CLHA at the time of cardiac evaluation:
The  cardiac  evaluation  was  done  after  six  months  from  identification  of  the 
retroviral  disease in 32 (31.7%) children;  between one to six months in 21 (20.8%) 
children and less than one month duration in 48(47.5%) children.  
The  CLHA  who  were  on  anti-retroviral  therapy  were  17.8%  and  82.2%  of 
children were not on antiretroviral therapy.
Categorisation of immune status based on CD-4 cell counts
The mean of their CD-4 cell  counts at the time of cardiac evaluation was 567 
cells/mm3. Of the 101 children, 30% had severe suppression of their CD-4 cell counts; 
37% children had moderate suppression and 33% had no suppression of their CD-4 cell 
counts  
(Fig: 4).
Analysis of cardiac symptomatology of the study group
On examination 44/101 (43.5%) CLHA had no symptoms and signs pertaining to 
the  cardiovascular  system.  Among  the  CLHA,  57(56.4%)  children  either  reported 
cardiac symptoms or on examination had clues to suggest  cardiac dysfunction. Most 
common symptoms among the CLHA were dyspnoea (40.5%) and easy fatiguability 
(35.6%). Exertional dyspnoea was present in 23.75% of cases. Chest pain was present in 
9  cases  (8.9%).  Palpitation  was  present  in  10  (9.9%)  CLHA.  In  the  children  who 
presented with oedema (10.4%), anaemia was present in 4 cases (3.9%) (Fig5). 
In  this  study  of  101  children,  46  had  cardiac  dysfunction  (45%).  Out  of  46 
children,  four  children  had  congestive  cardiac  failure  and  were  referred  for  cardiac 
evaluation.15  cases were referred for  cardiac evaluation based on clinical  suspicion. 
Rest of the children were evaluated as a part of the study. Congestive cardiac failure was 
associated with the following etiologies: dilated cardiomyopathy (2/46- 4%), ventricular 
septal defect (1/46- 2%) and pulmonary hypertension. 
On examination tachycardia and clubbing were significantly present in those with 
cardiac dysfunction. Eight cases presented with a murmur on examination. Cyanosis was 
present in two cases (TOF/Pulmonary hypertension). Gallop was present in three cases 
and all of them had dilated cardiomyopathy on cardiac evaluation (Fig: 6).
Association between age groups and cardiac dysfunction
Table 3: Association between age groups and cardiac dysfunction
Age
(yrs)
Cardiac dysfunction
Present Absent
n % n %
Total
n
P
Value
2-5 16 36.4 28 63.6 44
6-9 21 47.7 23 52.3 44
10-12 9 69.2 4 30.8 13
Total 46 45.5 55 54.5 101
0.104
The prevalence of cardiac dysfunction in the first group (2-5years) was 36.4%. In 
the second group (6-9years) the prevalence was 47.7%. In the third group the prevalence 
was 69.2%. Association between a particular age group and cardiac dysfunction was not 
statistically  significant  (p=0.104).  But  the  proportion  of  children  with  cardiac 
dysfunction was found to be increasing across the age groups(X2=0.039) (Table 3).
Association between sex and cardiac dysfunction
Table 4: Association between sex and cardiac dysfunction
Sex
Cardiac dysfunction
Present Absent
n % n %
Total
P
Value
Male 29 46.8 33 53.2 62
Female 17 43.6 22 56.4 39
Total 46 45.5 55 54.5 101
0.914
The prevalence of cardiac abnormality among the male children was 46.8% and 
that in female children was 43.6%. Among the CLHA who had cardiac dysfunction, 
male children were more common than female children, but this difference in proportion 
was not statistically significant (Table 4). 
Association between duration of illness and cardiac dysfunction 
Table 5: Association between duration of illness and cardiac dysfunction
Duration Of
Illness (months)
Cardiac dysfunction
Present Absent
n % n %
Total P value
0.348
< 1 27 56.3 21 43.8 48
1-6 4 19 17 81.0 21
>6 15 46.9 17 53.1 32
Total 46 45.5 55 54.5 101
The  prevalence  of  cardiac  dysfunction  in  the  CLHA  who  had  their  cardiac 
evaluation after 6 months of diagnosis of their retro viral disease was 46.9% (15 cases); 
between 1-6 months of diagnosis it was 19% and less than 1 month duration it  was 
56.3%.  The difference in proportion of CLHA who had cardiac dysfunction at different 
times of the course of the disease was not statistically significant (Table 5).  
Association  between  WHO  clinical  staging  for  Retroviral  disease  and  cardiac 
dysfunction                                                                                                                        
Table 6: Association between WHO clinical staging for Retroviral disease and 
cardiac dysfunction
Clinical 
stages
Cardiac dysfunction
Present Absent
n % n %
Total
P value
0.000
1 1 7.7 12 92.3 13
2 5 20.8 19 79.2 24
3 14 58.3 10 41.7 24
4 26 65.0 14 35.0 40
 
The prevalence of cardiac dysfunction in the CLHA under clinical stage I was 
7.7%, in stage II was 20.8%, stage III was 58.3% and in stage IV was     65%. The 
proportion of children with cardiac dysfunction was found to be significantly higher in 
stage IV compared to other stages (p<0.05). The proportion was increasing as the stages 
were advancing (x2= 0.000)  (Table 6).
Association between cardiac symptomatology and cardiac dysfunction
Table 7: Association between cardiac symptomatology and cardiac dysfunction
Cardiac 
examination
Cardiac dysfunction
Present Absent
n % n %
Total P value
0.535
Symptomatic 28 49.2 29 50.8 57
Asymptomatic 18 40.9 26 59.1 44
Total 46 45.5 55 54.5 101
    
Sensitivity=60.8%; Specificity=47.2%; PPV=49.1%; NPV=59%; Accuracy=53.4%
Among the  CLHA who  had  cardiac  dysfunction,  the  difference  in  proportion 
between cardio symptomatics  and asymptomatics  was not  statistically  significant.  (p 
value > 0.05).
Among the  46,  CLHA who had cardiac  dysfunction,  28  children  had cardiac 
symptoms (Sensitivity=60.8%).
Among the  55,  CLHA who had normal  cardiac  function,  26  children  had no 
cardiac symptoms (specificity = 47.2%).
Of the 57 children who had symptoms/signs pertaining to cardiovascular system, 
28 children showed cardiac dysfunction on echocardiography. (PPV=63%). Of the 44 
children who had no cardiac symptoms and signs, 26 children showed normal cardiac 
functional status (NPV=68%). The over all accuracy of the symptomatology to predict 
cardiac dysfunction is only 53.4%.
In the study, 18 children who had no cardiac symptoms and signs, had cardiac 
dysfunction on echocardiography. These children did not show any abnormality on X-
ray or ECG (Table 7).
Association  between  anaemia,  nutritional  status,  Immune  status  and  ART  and 
cardiac dysfunction.
Table 8:  Assessment of risk factors to predict cardiac dysfunction in CLHA
Variable Cardiac dysfunction
Present Absent
OR 95% CI P 
value
Anaemia Present 27 34
Absent 19 21
0.88 0.36–0.211 0.908
Undernourishment 
Present
34 36
Absent 12 19
1.5 0.58- 3.87 0.483
Immune  suppression 
Present
31 37
Absent 15 18
1.01 0.40 – 2.52 0.841
Antiretroviral  therapy 
Present
8 10
Absent 38 45
0.95 0.30 – 2.94 1.000
Among those who had cardiac dysfunction, patients who were anaemic, under 
nourished, immuno compromised or being treated with HAART, were more common, 
but the difference in proportion compared to cases in whom the above risk factors were 
absent was not statistically significant. Hence there was no positive correlation observed 
between anaemia, under nourishment, CD 4 cell counts and HAART therapy (Table 8).
Abnormalities observed on ECG in the CLHA
Table 9: ECG abnormalities in the CLHA
Electrocardiograph abnormalities n %
Sinus tachycardia 15 71
Right ventricular hypertrophy(RVH) 5 23
Left ventricular hypertrophy(LVH) 1 4
Right bundle branch block(RBBB) 2 9
Right atrial enlargement(RAE) 3 14
Non specific ST ,T changes 2 9
Among the ECG abnormalities, sinus tachycardia (71%) was the most common 
abnormality followed by right ventricular hypertrophy (23%). LVH was observed in one 
case with VSD. RBBB was observed in ASD and in isolation with mild LV dysfunction. 
Right atrial enlargement was seen in three (14%) cases; two children had pulmonary 
hypertension  and  one  had  DCM associated.  Non  specific  ST  segment  and  T  wave 
changes were observed in 9% of cases (Table 9). 
Echocardiographic abnormalities in the CLHA
Table 10: Echocardiographic abnormalities in the CLHA
Echo abnormalities n %
LV dilatation 43 42.6
LV dysfunction 36 35.6
LV hypertrophy 4 3.9
RV dysfunction 2 2
RV dilatation 2 2
Mitral regurgitation 2 2
Tricuspid regurgitation 6 5.9
Pericardial effusion 4 3.9
Pulmonary hypertension 4 3.9
Dilated cardiomyopathy 4 3.9
Congenital heart disease 3 3
The  most  common  abnormality  was  LV  dilatation  (42.6%)  followed  by  LV 
systolic dysfunction (35.6%). Isolated left ventricular hypertrophy was seen in 3% of the 
cases and 1 case presented with VSD. Valvular  (tricuspid and mitral)  regurgitations 
were seen in 7.9%. They were associated with DCM. In cardio asymptomatic CLHA, 
isolated LV dilatation and dysfunction was commonly observed.
Pericardial effusion was seen in 3.9%. Most of them were moderate effusions and 
none  had  cardiac  tamponade  and  required  tapping.  Two  cases  among  them  had 
tuberculosis.
DCM was noted in 3.9%. These patients were all seen in stage IV of the retroviral 
disease. They had recurrent chest infections and were highly compromised in clinical 
status. Among them 3 had congestive cardiac failure.
Congenital heart diseases accounted for 3% comprising of VSD, TOF and ASD. 
VSD was of large size and bidirectional shunt was present.
Only one case of pulmonary hypertension was associated with DCM. Two other 
children  had  pulmonary  hypertension  with  ventricular  dysfunction.  One  case  was 
primary pulmonary hypertension with normal cardiac function (Table 10).
Severity of cardiac dysfunction among the CLHA
Table 11: Grading of dysfunction based on Ejection fraction
Ejection fraction N %
Severe (<20%) 4 3.9
Moderate (20-35%) 23 22.7
Mild (35-53%) 15 14.8
Normal (>/=54%) 59 58.4
Table 12: Grading of dysfunction based on Fractional shortening
Fractional shortening n %
Severe (<19%) 4 3.9
Moderate (19-24%) 29 11.8
Mild (25-27%) 12 28.7
Normal (>/=28%) 55 54.4
In 59 children there was normal ejection fraction (>54%). The four children who 
had DCM had severe cardiac dysfunction and both EF and FS were less than 20%. 
Moderate impairment was seen in 29 (28.7%) cases.
Fractional shortening was compromised in 46 children. Out of the 46 children, 4 
(3.9%) had severe impairment in fractional shortening (<19%); 12 (11.8%) children had 
moderate reduction. Mild impairment (25-27%) was seen in 29(28.7%) children.
Both EF and FS were reduced in 35.6% cases. Severe ventricular dysfunction was 
present in 4 cases. All of them had DCM and were in the stage IV of the retroviral 
disease. Moderate impairment of systolic dysfunction was present in 23 cases. Among 
these children most of them had clues to suggest cardiac dysfunction. Mild impairment 
was present in 15 cases. CLHA who had mild impairment of cardiac dysfunction were 
asymptomatic  clinically.  Cardiac symptoms were usually  present  in CLHA who had 
moderate impairment of cardiac function (Table 11      and 12). 
Association between chest x-ray and cardiac dysfunction
Table 13: Association between chest x-ray and cardiac dysfunction
Chest X-ray Cardiac dysfunction
Present Absent
Total
P value
Abnormal 10 0 10
Normal 36 55 91
Total 46 55 101
0.001
Sensitivity=21.7%; Specificity=100%; PPV=100%; NPV=35.9%; Accuracy=64.3%.
Of  the  46  children  who  had  cardiac  dysfunction  on  echo,  chest  radiography 
showed cardiomegaly in 10 cases (sensitivity-21.7%). In the 55 children who had their 
cardiac  functional  indices  to  be  normal  on  echo,  none  showed  any  abnormality  in 
cardiac size (specificity 100%). In all the cases where chest x ray was abnormal ECHO 
was also abnormal (PPV=100%). Among the 91 cases where the chest x ray was normal 
Echo was able to pick up abnormalities in 36 cases (NPV=35.9%). The overall accuracy 
of chest x ray in predicting cardiac dysfunction was only 64.3% (Table 13).
Association between ECG and cardiac dysfunction
Table 14: Association between ECG and cardiac dysfunction
ECG Cardiac dysfunction
Present Absent
Total P value
Abnormal 16 5 21
Normal 30 50 80
Total 46 55 101
0.003
Sensitivity=34.8%;  Specificity=90.9%;  PPV=76.1%;  NPV=62.5%;  Accuracy=65.3% 
(p=0.003) 
ECG showed  abnormalities  in  21  cases.  Of  the  46  children  who  had  cardiac 
dysfunction on echo, ECG showed abnormalities in 16 cases (sensitivity=34.8%).
In 55 children who had normal cardiac function, ECG was normal in 50 cases 
(specificity=90.9%). Among 21 cases who showed abnormalities on ECG, Echo picked 
up abnormalities in 16 cases (PPV=76.1%). In 80 cases with normal ECG, Echo was 
also  normal  in  50  cases  (NPV=62.5%).  The  overall  accuracy  of  ECG in  predicting 
cardiac dysfunction was 65.3% (Table 14).
Association  between  combination  of  both  chest  x  ray  and  ECG  and  cardiac 
dysfunction
Table 15:  Association between combination of both chest x ray and ECG and 
cardiac dysfunction
Investigations
Cardiac 
dysfunction
Present Absent
Sensitivity Specificity P value
Chest x ray
Abnormal 
Normal
10
36
0
55
21.7 100 0.001
ECG
Abnormal
Normal
16
5
30
50
34.8 90.9 0.003
Chest x ray
and ECG (-)
Abnormal
Normal
7
39
0
55
15.2 100 0.009
Sensitivity=15.2% specificity=100% NPV=58.5% PPV=100% Accuracy=61.3%
Among 46 CLHA who had cardiac dysfunction, 7 cases had abnormality on both 
ECG and chest x ray (sensitivity = 15.2% ).
When  the  results  of  chest  radiography  and  ECG were  combined  (when  both 
showed abnormalities), the specificity was 100%, but the sensitivity decreased to 15.2% 
because  in  three  cases  where  the  X ray  was  abnormal  the  ECG did  not  show any 
abnormality. Among the 7 cases that showed abnormality in both investigations, cardiac 
dysfunction was present in all the 7 cases (Positive predictive value on combining both 
was  100%).  Among  94  cases  who  either  did  not  show  any  abnormality  or  had 
discordance  between  each  other,  cardiac  function  was  normal  in  55  cases  (negative 
predictive value was 58.5%).  The  overall  accuracy of  the combination  in  predicting 
cardiac dysfunction was 61.3% (Table 15).     
DISCUSSION
Infection by the HIV is one of the major public health problems in the world, with 
high  mortality  and  morbidity  rates.  There  is  a  worldwide  trend  of  increasing 
transmission among women at child bearing age, which leads to increased mother to 
child transmission and pediatric HIV cases.4
Highly active anti retroviral therapy has significantly changed the course of the 
disease with increased survival and improved quality of life for AIDS patients.34 But 
ARV drugs do not eliminate the virus from the body; their use may simply postpone the 
development  of  the  complications  of  the  infection.  All  body  systems  including  the 
cardiovascular system, may be affected by HIV infection.34 Cardiac disease associated 
with HIV infection is an underestimated condition because the signs and symptoms are 
nonspecific  and  are  often  attributed  to  pulmonary  pathologies  by  the  physician  and 
patients  are  not  routinely  evaluated  by  echocardiography.  Several  patterns  of 
cardiovascular involvement have been reported in CLHA by various studies in other 
parts of the world.
Review of the Indian literature showed a paucity of similar data from the Indian 
subcontinent which holds a considerable number of PLHA. A single study of cardiac 
diseases in pediatric HIV patients had used a very  small sample size (n=26).7 Hence this 
study  was  undertaken  to  determine  the  prevalence  and  clinical  spectrum of  cardiac 
abnormalities among the CLHA in the age group of 2 to 12 years.
The  choice  of  this  age  group  (2-12  years)  excludes  patients  with  the  rapidly 
progressive form who evolve to death within the first 2 years of life.12,5 Therefore, the 
priority was to study patients with slow progression seen in the older age group (toddler, 
childhood,  adolescents)  with  higher  probability  of  cardiac  involvement12,17 and 
therapeutic interventions.13
In this study, there were 101 CLHA between 2-12 years of age. These children 
after  clinical  examination  and  hemoglobin  and  CD-4  cell  count  estimation  were 
subjected to cardiac evaluation. 
Most of them had acquired the infection by perinatal transmission. The mean age 
of the CLHA (6 years) and a large number of the CLHA in the advanced stage of the 
disease was similar  to the previous study.3  Many of them were undernourished.  The 
difference in proportions between the two sexes across different age groups was not 
significant. In our study, CLHA had varied clinical presentations in addition to failure to 
thrive.  The  commonest  were  hepatosplenomegaly,  lymphadenopathy  and  oral 
candidiasis similar to the previous Indian study.7
Among the CLHA 19 cases were referred for cardiac evaluation based on clinical 
suspicion.  Rest  of  the  cases  were  evaluated  as  a  part  of  the  study.  After  cardiac 
evaluation  in  101 CLHA, the  prevalence  of  cardiac  abnormalities  in  our  study  was 
45.5% similar to the previous studies.3, 2, 1 
In our study there  was no positive association between particular  sex and the 
prevalence  of  cardiac  abnormalities.  This  was  not  in  accordance  with  the  study42 
conducted earlier which showed a positive association with the male sex which could 
not be explained biologically.
The prevalence among different age groups was different, showing an increasing 
trend across the age groups in our study. This was similar to the study by Pong port et al6 
which showed no correlation between particular age group and cardiac involvement. 
Among the CLHA with cardiac dysfunction most of them belonged to advanced 
clinical stages of the retroviral disease. In our study, the duration of illness did not have 
any significant association with the occurrence of cardiac abnormalities which may be 
due to only few cases among particular duration strata distracting the values.
The prevalence of cardiac involvement among the children who had no signs and 
symptoms pertaining to cardiovascular system in our study was 40.9% compared to the 
previous  study  by  Ira  shah  et  al  which  showed  72% prevalence  among  the  cardio 
asymptomatics,7 but this was a pilot study done in a small group of patients (n=26). 
Among  the  CLHA  with  cardiac  dysfunction  there  was  no  significant  statistical 
difference  between the  proportions  of  CLHA with  cardiac  symptoms and signs  and 
without cardiac symptoms and signs. This emphasizes the need for all the CLHA to be 
screened for cardiac involvement irrespective of whether they have symptoms and signs 
related to cardiac dysfunction.
In our study, the CD-4 cell counts did not correlate statistically with the presence 
of  cardiac  dysfunction.  This  observation  was  similar  to  that  of  P2C2 study.9  This  is 
explained  by  the  fact  that  CD-4  cell  count  is  a  correlate  of  the  progression  of  the 
biological effects of viral infection on the immune system, but it does not indicate the 
magnitude of the clinical effects.
In  our  study  the  proportions  of  CLHA  with  cardiac  dysfunction   across  the 
different  grades  of  anemia  were  not  statistically  significant.  There  was  no  positive 
correlation between nutritional status (wasting) and cardiac dysfunction in the CLHA 
similar to the observation made by Lubega et al3, Pong port et al6  and P2C2 study9. The 
reason is that unlike other states of malnutrition in which LV mass falls as weight and 
height fall, the demands of mechanically driven LV hypertrophy take precedence over 
the catabolic influence of wasting in HIV patients. There appears to be a sparing effect 
of cardiac mass relative to skeletal muscle wasting in HIV infected children.30 When this 
protective  effect  wears  out,  cardiac  dysfunction  ensues  which  is  indicated  by  the 
observation that all patients with DCM were highly compromised in clinical status. They 
suffered  from  severe  malnutrition  recurrent  respiratory  tract  infections  and  chronic 
anemia, an observation made by the previous study2 and our study.
Our study did not  show any statistical  correlation between therapy with ARV 
drugs and presence of cardiac abnormalities. Domanski et al33 reported cardio toxicity 
due  to  zidovudine  among the  PLHA.  Lipshultz  et  al32 concluded  that  there  was  no 
increased cardiac abnormalities among those who were treated with zidovudine.  Our 
study was unable to infer on this since long term follow up of patients on HARRT was 
not there in our study.
In our study the prevalence of cardiac abnormalities among CLHA detected by 
Echocardiography was 45.5%. Other studies3,2,1,4,6 have also reported a similar range. The 
data published about this prevalence vary according to the methodology used, time of 
collection, profile of children studied and type of therapy used.18 The spectrum of cardiac 
abnormalities among CLHA in our study is as follows: LV dilatation in isolation and in 
combination  with  LV dysfunction,  LV hypertrophy,  RV dilatation,  RV dysfunction, 
dilated cardiomyopathy,  valvular  (tricuspid,  mitral)  regurgitation,  pericardial  effusion 
and pulmonary hypertension. 
Our  study  observed  LV dilatation  as  the  most  common abnormality  with  the 
prevalence of 42.6% which accords with the previous Indian study7. The prevalence of 
isolated LV dilatation which signifies the initial stages of cardiac dysfunction, in our 
study was 6.9% in contrast to reports of studies1,4 from other parts of the world claiming 
10-20%.  The  reason  being different  clinical  profile  of  the  CLHA who presented  in 
advanced stage of the disease in our study. The prevalence of LV dysfunction in our 
study was 35.6% which is higher compared to that reported  by the  previous Indian 
study probably because in the previous study most of the cases were asymptomatic for 
cardiac  illness  and  hence  had more  of  LV hypertrophy,  an  earlier  phase  of  cardiac 
pathology rather than dysfunction7
Prospective studies have shown that LV dysfunction may progress to DCM. The 
prevalence of DCM in our study was 4%. This was similar to the study by Lubega et al 
(3.8%) from South Africa and much lower than that reported by Sherron et al (45%)21 
and Lipshultz et al  (16%)22   from the west. This could probably be explained by the 
increased  life  span  and  advanced  cardiac  disease  accounted  by  early  and  effective 
therapeutic  interventions  in  CLHA  in  the  western  world  compared  to  the 
underprivileged and clinically  compromised CLHA in  the  developing countries  who 
succumb very early without treatment, even before HAART.
Pericardial effusion was seen in 3.9% in our study. Some studies have reported 
14-16%7,21,22  and some found no pericardial effusion even in a sample larger than our 
study. The prevalence of pulmonary hypertension was 3.9% in our study, similar to the 
study by Diogenes et al2 (4.8%). This is lower compared to previous studies  which were 
either  follow  up  studies6 or  retrospective  studies  with  small  sample  size12.The 
abnormalities  like  DCM,  pericardial  effusion  and  pulmonary  hypertension  were 
observed more commonly in the advanced clinical stage of the retroviral disease in our 
study similar to other studies 2,3 .
The prevalence of congenital heart defects was 3% in our study. This is similar 
(2-3%)  to  the  previous  studies24,23,22   and  higher  than  that  found  in  the  general 
population(0.8%).  25 The defects observed were ASD which was asymptomatic, VSD 
which  presented  with  congestive  cardiac  failure  and  TOF,  all  of  them with  normal 
cardiac function. These defects may be due to the foetal and congenital effects of HIV 
infection.
The prevalence of ECG abnormalities in our study was 20.7%.This is similar to 
the prevalence in the study by Lubega et al3 which also used standard 12 lead standard 
ECG and lower than Issenberg et al31,10 (55%) and Lipshultz et al22 (93%) who have used 
24 hour ambulatory ECG in addition to standard 12 lead ECG. 
The spectrum of abnormalities observed in ECG were sinus tachycardia,  right 
ventricular hypertrophy, right bundle branch block, left ventricular hypertrophy, right 
atrial enlargement, non specific ST and T wave changes. Sinus tachycardia was the most 
common abnormality similar to the previous study.3 
In our cardiac evaluation, Chest X ray was abnormal showing cardiomegaly only 
in  9.9%  of  cases.  When  the  chest  X  ray  was  abnormal  there  was  definitely  an 
abnormality picked by ECHO. Hence the specificity was high (100%). In the chest x-ray 
often there was no cardiomegaly despite ECHO proven disease similar to the previous 
study.22 In 36 cases it failed to detect the cardiac abnormalities. The sensitivity was low 
(21.7%). The chest X ray was positive in advanced lesions and negative in the early 
stages of cardiac involvement.  Therefore the role of chest X ray as a screening tool 
among the CLHA to detect the early cardiac involvement was limited.
Though ECG revealed some clinically  in  apparent  disease,  the sensitivity  was 
only 34.8% (more compared to chest X ray) and specificity was 90.9% (less than chest x 
ray). Its accuracy to predict cardiac involvement was only 65.3%. It failed to pick up the 
early stage of LV dysfunction which was sub clinical.
 ECHO picked up abnormalities in 45.5% cases. It was able to detect the early 
changes like LV dilatation, LV systolic dysfunction, LV hypertrophy in addition to the 
advanced  stages  of  involvement  like  DCM,  pericardial  effusion,  pulmonary 
hypertension and valvular regurgitations and congenital defects. It was able to detect 
cardiac abnormalities even in patients who had no symptoms and signs pertaining to the 
cardiovascular  system.  Therefore  ECHO  was  the  only  non  invasive  investigatory 
modality  to  detect  cardiac  involvement  in  the  early  stage  for  early  therapeutic 
intervention.
Both ECG and X-ray chest proved to be poor screening tools for cardiac disease 
among the CLHA and ECHO serves as the single most useful, noninvasive diagnostic 
test to detect cardiac dysfunction in CLHA even in early stages. 
Thus it is emphasized that all the CLHA have to be evaluated for cardiac disease 
with Echocardiography irrespective of whether they have symptoms and signs related to 
cardiac dysfunction.
SUMMARY
To summarise the results of the study,
• The  prevalence  of  cardiac  dysfunction  among  the  CLHA  was  45.5%.  The 
prevalence was more among those who presented in the advanced clinical stages 
of the retroviral disease. The prevalence was found to be increasing across the age 
groups.
• The  prevalence  of  cardiac  dysfunction  did  not  correlate  with  sex,  nutritional 
status, haemoglobin levels and CD-4 cell counts.
• Among those who had cardiac dysfunction there was no significant difference in 
proportions between those who had symptoms and signs pertaining to  cardiac 
dysfunction and those who did not have the symptoms and signs. This emphasizes 
the need for all the CLHA to be screened for cardiac involvement irrespective of 
whether they have symptoms and signs related to cardiac dysfunction.
• The spectrum of cardiac abnormalities observed on ECHO were LV dilatation, 
LV dysfunction, LV hypertrophy, DCM, RV dilatation, RV dysfunction, tricuspid 
and  mitral  regurgitation,  pericardial  effusion,  pulmonary  hypertension  and 
congenital cardiac defects (ASD,VSD,TOF). The most common of them was LV 
dilatation (42.6%) followed by LV dysfunction (35.6%).
• The electrocardiography showed  abnormalities in 20.6% cases. The spectrum of 
abnormalities  observed  in  ECG  were  sinus  tachycardia  (commonest  change), 
RVH, RBBB, RAE, LVH and    non-specific ST and T wave changes.
• Chest x ray had high specificity but a low sensitivity.
• ECG had better sensitivity than chest x ray, but was able   to detect abnormality 
only in 16 cases with cardiac dysfunction.  
• Chest x-ray and ECG failed to pick up the abnormalities in the early stages of 
cardiac dysfunction.
• Echocardiography was able to detect abnormalities even in the early stages of the 
dysfunction  when  the  abnormality  was  subtle  and  sub  clinical.  Hence  ECHO 
serves as  the single  most  useful  non-invasive diagnostic  test  to  detect  cardiac 
dysfunction. 
Hence, chest x-ray and ECG were poor screening tools to detect the abnormalities 
making ECHO the only non invasive investigation to detect the dysfunction for early 
cardiac intervention.
All  the  CLHA  have  to  be  evaluated  for  cardiac  involvement  irrespective  of 
whether  they  have  symptoms  and  signs  related  to  cardiac  dysfunction  with  the 
echocardiogram. 
CONCLUSION
It was observed that the prevalence of cardiac dysfunction among the CLHA was 
significant (45.5%). 
Chest  X  ray  and  ECG  were  poor  screening  tools  to  detect  early  cardiac 
involvement. 
Echocardiogram is found to be a promising investigatory modality to detect early, 
subtle, sub clinical and progressive cardiac abnormalities.
Therefore  it  is  suggested  that  all  the  CLHA undergo  echocardiography  as  an 
important investigation irrespective of whether they are symptomatic or asymptomatic 
with reference to cardiac dysfunction and periodic screening thereafter.
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ANNEXURES
ANNEXURE I
Data entry form
Serial No:
Name:
Age:
Sex:
Father name:
Address:
HIV status of the parents:
Mother: Alive / Dead
Positive /Negative
Father: Alive / Dead 
Positive/Negative
Probable mode of transmission:
Date of diagnosis of RVD:
Date of cardiac evaluation:
H/O Presenting complaints:
History pertaining to cardiovascular system:
Breathlessness on exertion:
Fatigue:
Chest pain:
Palpitations:
Bluish discolouration of tongue and nail beds:
Syncope:
Oedema:
Examination
General Examination
Sensorium:
Tachypnoea / Dyspnoea:
Nutritional status:
Pallor:
Clubbing:
Cyanosis:
Lymphadenopathy:
Oedema:
Jugular venous pressure:
Anthropometry
Weight:
Height:
Vitals
Temperature:
Respiratory rate:
Heart rate:
Blood pressure:
Cardiovascular system
Inspection
Position of the apical impulse :
Precordial bulge:
Visible pulsations/dilated veins:
Palpation
Apex
Parasternal heave
Palpable second heart sound
Thrills
Percussion
Heart borders
Auscultation
Heart sounds 
Murmurs
Miscellaneous sounds-Ejection clicks / Opening snaps / Pericardial rub
Respiratory system
Tracheal deviation
Breath sounds
Added sounds
Abdomen
Organomegaly
Nervous system
Higher functions
Focal neurological deficit
Stage of retroviral disease:
Diagnosis:
Investigations
Hemoglobin
CD-4 cell counts
Cardiac evaluation
Chest X ray
ECG 
    ECHO
                   Ejection Fraction
          Fractional shortening
          Right ventricle dimension in systole
            in diastole
Left ventricle dimension in systole
           in diastole
Thickness of LV posterior wall in diastole
Thickness of interventricular septum in diastole
Dilated cardiomyopathy 
Pericardial effusion
Septal defects
Other abnormalities 
Doppler and colour flow studies
    Pulmonary artery pressure
   Valvular regurgitation 
TR gradient
PR gradient
ANNEXURE: 2
WHO REVISED CLINICAL STAGING IN HIV/AIDS CHILDREN
Clinical stage 1:
• Asyptomatic
• Persistent generalised lymphadenopathy
Clinical stage 2 :
• Unexplained persistent hepatosplenomegaly
• Papular pruritic eruptions 
• Extensive wart virus infection
• Extensive molluscum contagiosum
• Recurrent oral ulcerations
• Unexplained persistent parotid enlargement
• Linear gingival erythema
• Herpes zoster
• Recurrent or chronic respiratory tract infections (otitis media, otorrhoea, sinusitis, 
tonsillitis)
Fungal nail infections
Clinical stage 3:
• Moderate unexplained malnutrition not adequately responding to standard therapy
• Unexplained persistent diarrhoea(14 days or more)
• Unexplained persistent fever (above 37.5 intermittent or constant ,for longer than 
1 month)
• Persistent oral candida(outside first 6 to 8 weeks of life)
• Oral hairy leukoplakia
• Acute necrotising ulcerative gingivitis/peri odontitis/TB lymphadenitis
• Pulmonary TB
• Severe recurrent persumed bacterial pneumonia
Symptomatic lymphoid interstitial pneumonitis
Chronic HIV associated lung disease including bronchiectasis
• Unexplained  anaemia  (less  than  8  gm%),neutropenia(less  than  500/c.mm)  or 
chronic thrombocytopenia (less than 50000/c.mm)
• HIV associated cardiomyopathy or HIV associated nephropathy
Clinical stage 4:
• Unexplained severe wasting,stunting  or  severe  malnutrition  not  responding to 
standard therapy
• Pneumocystis pneumonia
• Recurrent  severe  presumed  bacterial  infactions  (e.g.empyema,  polymyositis, 
bone or joint infection, meningitis but excluding pneumonia)
• Chronic herpes simplex infection (orolabial or cutaneous of more than 1 month 
duration or visceral at any site)
• Extrapulmonary TB
• Kaposi sarcoma
• Oesophageal candidiasis (or candida of trachea, bronchi or lungs)
• CNS toxoplasmosis (outside the neonatal period)
o HIV encephalopathy
• CMV infection; retinitis, or CMV infection affecting another organ with onset, at 
age over 1 month
• Extra pulmonary cryptococosis including meningitis
• Disseminated  endemic  mycosis  (extra  pulmonary  histoplasmosis, 
coccidiomycosis, penniciollosis)
• Chronic cryptosporidiosis
• Chronic isosporiosis
• Disseminated non tuberculus mycobacterail infection
• Cerebral or B cell non hodgkins lymphoma
• Acquired HIV associated rectal fistula
• Progressive multifocal leucoencephalopathy
ANNEXURE : 3
PEDIATRIC IMMUNOLOGICAL CLASSIFICATION (CDC)
Immune 
category
< 12 months 1–5 years 6 –12 years
No./mm3 % No./ 
mm3
% No./ 
mm3
%
Category 1:
No 
suppression
≥ 1500 ≥ 25% ≥ 1000 ≥ 25% ≥ 500 ≥ 25%
Category 2:
Moderate 
750–1499 15%–
24%
500–999 15%–
24%
200–499 15%–24%
Category 3:
Severe 
<750 <15% <500 <15% <200 <15%
ABBREVIATIONS
ARV- Anti Retro Viral
PLHA- Person Living with HIV/AIDS
CLHA- Children Living with HIV/AIDS
HIV-Human Immunodeficiency Virus
AIDS-Acquired Immuno Deficiency Syndrome 
CD- Cluster Differentiation
TNF- Tumor Necrosis Factor
TGF- Tumor Growth Factor
ffPCR- Polymerase Chain Reaction
DCM- Dilated Cardio Myopathy
IL- Inter Leukin
RV- Right Ventricle
LV- Left Ventricle
HAART- Highly Active Anti Retroviral Therapy 
ECG-Electro Cardio Graph
ECHO- Echocardiography
Ig- Immunoglobulin
EF- Ejection Fraction
FS-Fractional Shortening
TR –Tricuspid regurgitation ,  PR- Pulmonary regurgitation

